Asymmetric contribution of α and β subunits to the activation of αβ heteromeric glycine receptors

被引:26
作者
Shan, Q [1 ]
Nevin, ST [1 ]
Haddrill, JL [1 ]
Lynch, JW [1 ]
机构
[1] Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia
关键词
allosteric interactions; gating; glycine receptor chloride channel; receptor structure and function; substituted cysteine accessibility method;
D O I
10.1046/j.1471-4159.2003.01872.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study investigated the role of beta subunits in the activation of alphabeta heteromeric glycine receptor (GlyR) chloride channels recombinantly expressed in HEK293 cells. The approach involved incorporating mutations into corresponding positions in alpha and beta subunits and comparing their effects on receptor function. Although cysteine-substitution mutations to residues in the N-terminal half of the alpha subunit M2-M3 loop dramatically impaired the gating efficacy, the same mutations exerted little effect when incorporated into corresponding positions of the beta subunit. Furthermore, although the alpha subunit M2-M3 loop cysteines were modified by a cysteine-specific reagent, the corresponding beta subunit cysteines showed no evidence of reactivity. These observations suggest structural or functional differences between alpha and beta subunit M2-M3 loops. In addition, a threonine-->leucine mutation at the 9' position in the beta subunit M2 pore-lining domain dramatically increased the glycine sensitivity. By analogy with the effects of the same mutation in other ligand-gated ion channels, it was concluded that the mutation affected the GlyR activation mechanism. This supports the idea that the GlyR beta subunit is involved in receptor gating. In conclusion, this study demonstrates that beta subunits contribute to the activation of the GlyR, but that their involvement in this process is significantly different to that of the alpha subunit.
引用
收藏
页码:498 / 507
页数:10
相关论文
共 45 条
[1]   Openings of the rat recombinant α1 homomeric glycine receptor as a function of the number of agonist molecules bound [J].
Beato, M ;
Groot-Kormelink, PJ ;
Colquhoun, D ;
Sivilotti, LG .
JOURNAL OF GENERAL PHYSIOLOGY, 2002, 119 (05) :443-466
[2]   UNCONVENTIONAL PHARMACOLOGY OF A NEURONAL NICOTINIC RECEPTOR MUTATED IN THE CHANNEL DOMAIN [J].
BERTRAND, D ;
DEVILLERSTHIERY, A ;
REVAH, F ;
GALZI, JL ;
HUSSY, N ;
MULLE, C ;
BERTRAND, S ;
BALLIVET, M ;
CHANGEUX, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) :1261-1265
[3]   Paradoxical allosteric effects of competitive inhibitors on neuronal alpha 7 nicotinic receptor mutants [J].
Bertrand, S ;
DevillersThiery, A ;
Palma, E ;
Buisson, B ;
Edelstein, SJ ;
Corringer, PJ ;
Changeux, JP ;
Bertrand, D .
NEUROREPORT, 1997, 8 (16) :3591-3596
[4]   Mutation of the 9′ leucine in the GABAA receptor γ2L subunit produces an apparent decrease in desensitization by stabilizing open states without altering desensitized states [J].
Bianchi, MT ;
Macdonald, RL .
NEUROPHARMACOLOGY, 2001, 41 (06) :737-744
[5]   Probing the structure of the nicotinic acetylcholine receptor ion channel with the uncharged photoactivable compound [3H]diazofluorene [J].
Blanton, MP ;
Dangott, LJ ;
Raja, SK ;
Lala, AK ;
Cohen, JB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (15) :8659-8668
[6]   RESIDUES WITHIN TRANSMEMBRANE SEGMENT M2 DETERMINE CHLORIDE CONDUCTANCE OF GLYCINE RECEPTOR HOMO-OLIGOMERS AND HETEROOLIGOMERS [J].
BORMANN, J ;
RUNDSTROM, N ;
BETZ, H ;
LANGOSCH, D .
EMBO JOURNAL, 1993, 12 (10) :3729-3737
[7]   Allosteric activation mechanism of the α1β2γ2 γ-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine [J].
Chang, YC ;
Weiss, DS .
BIOPHYSICAL JOURNAL, 1999, 77 (05) :2542-2551
[8]   Substitutions of the highly conserved M2 leucine create spontaneously opening ρ1 γ-aminobutyric acid receptors [J].
Chang, YC ;
Weiss, DS .
MOLECULAR PHARMACOLOGY, 1998, 53 (03) :511-523
[9]  
Chen ZM, 1998, STUD APPL ELECTROMAG, V14, P225
[10]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924